Effects on imidazoacridinone C-1311 on the transcriptomic profile in prostate cancer cell depending on their AR status.
Human prostate cancer cells, LNCaP (AR+) and DU-145 (AR-), were treated with C-1311 to identify the transcriptomic profile and functionally relevant androgen-dependent and independent genes using RNA sequencing. Overall design: We examined the anti-prostate cancer properties of imidazoacridinone, C-1311. Using RNAseq we showed for the first time that C-1311 is a promising agent that targets the androgen receptor pathway by blocking AR transcriptional activity and has potent efficacy towards prostate cancer cells.